<DOC>
	<DOCNO>NCT00117676</DOCNO>
	<brief_summary>This primary objective study compare efficacy , safety , tolerability tenofovir disoproxil fumarate ( TDF ) versus adefovir dipivoxil ( ADV ) treatment pre-core mutant chronic hepatitis B . Participants receive TDF ADV 48 week ( double-blind ) . After 48 week , eligible participant switch open-label TDF 480 week .</brief_summary>
	<brief_title>A Study Compare Tenofovir Disoproxil Fumarate Versus Adefovir Dipivoxil Treatment HBeAg-Negative Chronic Hepatitis B</brief_title>
	<detailed_description />
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis A</mesh_term>
	<mesh_term>Hepatitis , Chronic</mesh_term>
	<mesh_term>Hepatitis B</mesh_term>
	<mesh_term>Hepatitis B , Chronic</mesh_term>
	<mesh_term>Tenofovir</mesh_term>
	<mesh_term>Adefovir</mesh_term>
	<mesh_term>Adefovir dipivoxil</mesh_term>
	<criteria>Key Chronic hepatitis B virus ( HBV ) infection , define positive serum hepatitis B santigen ( HBsAg ) least 6 month . 18 69 year age , inclusive . Active hepatitis B eantigen ( HBeAg ) negative chronic HBV infection , follow : HBeAg negative HBeAb positive screening Alanine aminotransferase ( ALT ) level &gt; upper limit normal range ( ULN ) ≤ 10 x ULN Serum HBV DNA &gt; 100,000 copies/mL screen Creatinine clearance ≥ 70 mL/min Hemoglobin ≥ 8 g/dL Neutrophils ≥ 1,000 /mL Knodell necroinflammatory score ≥ 3 Knodell fibrosis score &lt; 4 ; however , 120 patient cirrhosis , ie , Knodell fibrosis score equal 4 , eligible enrollment Negative serum βhuman chorionic gonadotropin ( hCG ) Nucleotide naive , ie , prior nucleotide ( TDF ADV ) therapy great 12 week Nucleoside naive , ie , prior nucleoside ( nucleoside ) therapy great 12 week . However , 120 patient &gt; 12 week prior lamivudine experience eligible Willing able provide write informed consent Had liver biopsy perform within 6 month baseline readable biopsy slide agree biopsy perform prior baseline Key Pregnant woman , woman breast feeding , woman believe may wish become pregnant course study Males females reproductive potential unwilling use effective method contraception study . Decompensated liver disease define conjugated bilirubin &gt; 1.5 x ULN , prothrombin time ( PT ) &gt; 1.5 x ULN , platelets &lt; 75,000/mL , serum albumin &lt; 3.0 g/dL , prior history clinical hepatic decompensation ( eg , ascites , jaundice , encephalopathy , variceal hemorrhage ) Received nucleoside , nucleotide ( TDF ADV ) interferon ( pegylated ) therapy within 6 month prior pre treatment biopsy Evidence hepatocellular carcinoma ( HCC ) Coinfection hepatitis C virus ( HCV ) , human immunodeficiency virus ( HIV ) , hepatitis D virus ( HDV ) Significant renal , cardiovascular , pulmonary , neurological disease Received solid organ bone marrow transplantation Is currently receive therapy immunomodulators ( eg , corticosteroid , etc . ) , investigational agent , nephrotoxic agent , agent susceptible modify renal excretion Has proximal tubulopathy Note : Other protocol define Inclusion/Exclusion criterion may apply .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>69 Years</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>tenofovir</keyword>
	<keyword>adefovir</keyword>
	<keyword>hepatitis B virus</keyword>
	<keyword>HBeAg Negative</keyword>
</DOC>